CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,812,468
- in 11 filings, $79.8M under 10b5-1 plans
Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-14 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +6,250 | $8.93 | $56K | 57,830 |
| 2026-04-14 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +6,500 | $20.46 | $133K | 64,330 |
| 2026-04-14 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −21,977 | $41.07 | $903K | 42,353 |
| 2026-04-14 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −2,500 | 5,000 | ||
| 2026-04-14 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −6,250 | 12,500 | ||
| 2026-04-14 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −6,500 | 19,500 | ||
| 2026-04-14 | Baynes Roy D. Director | Option exercise 10b5-1 | +8,000 | $17.94 | $144K | 45,500 |
| 2026-04-14 | Baynes Roy D. Director | Option exercise 10b5-1 | +9,000 | $15.43 | $139K | 54,500 |
| 2026-04-14 | Baynes Roy D. Director | Option exercise 10b5-1 | +4,500 | $18.27 | $82K | 59,000 |
| 2026-04-14 | Baynes Roy D. Director | Option exercise 10b5-1 | +4,500 | $21.38 | $96K | 63,500 |
| 2026-04-14 | Baynes Roy D. Director | Option exercise 10b5-1 | +6,750 | $17.11 | $115K | 70,250 |
| 2026-04-14 | Baynes Roy D. Director | Sale 10b5-1 | −26,000 | $41.07 | $1.1M | 44,250 |
| 2026-04-14 | Baynes Roy D. Director | Sale 10b5-1 | −6,750 | $42.12 | $284K | 37,500 |
| 2026-04-14 | Baynes Roy D. Director | Option exercise · Stock option (right to buy) 10b5-1 | −8,000 | 0 | ||
| 2026-04-14 | Baynes Roy D. Director | Option exercise · Stock option (right to buy) 10b5-1 | −9,000 | 0 | ||
| 2026-04-14 | Baynes Roy D. Director | Option exercise · Stock option (right to buy) 10b5-1 | −4,500 | 4,500 | ||
| 2026-04-14 | Baynes Roy D. Director | Option exercise · Stock option (right to buy) 10b5-1 | −4,500 | 4,500 | ||
| 2026-04-14 | Baynes Roy D. Director | Option exercise · Stock option (right to buy) 10b5-1 | −6,750 | 6,750 | ||
| 2026-04-14 | LYONS GARY A Director | Option exercise 10b5-1 | +8,000 | $16.33 | $131K | 65,500 |
| 2026-04-14 | LYONS GARY A Director | Sale 10b5-1 | −8,000 | $41.07 | $329K | 57,500 |
Page 10 of 51 · 1,020 trades